Report cover image

Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025

Publisher GlobalData
Published Dec 30, 2025
Length 635 Pages
SKU # GBDT20810797

Description

Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025

Summary

GlobalData's clinical trial report, “Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025 provides an overview of Gastroesophageal (GE) Junction Carcinomas Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

635 Pages
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas
Nov 25, 2025: Imfinzi Approved in the US as First and Only Perioperative Immunotherapy for Patients With Early Gastric and Gastroesophageal Cancers
Nov 07, 2025: Marengo Presents Oral Presentation Highlights Single-Agent of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
Oct 30, 2025: Foghorn Therapeutics Announces Updates for Selective ARID1B Program
Oct 28, 2025: Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
Oct 22, 2025: I-Mab To Present Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Oct 20, 2025: First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Oct 20, 2025: Sichuan Kelun-Biotech Biopharmaceutical Announced Presentation On SKB-315 at the 2025
European Society for Medical Oncology (ESMO) Congress
Oct 20, 2025: Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
Oct 17, 2025: IMFINZI-Based Regimen Reduced the Risk of Death by 22% in Early Gastric Cancer vs. Chemotherapy Alone in MATTERHORN Phase III Trial
Oct 17, 2025: Mixed Outcomes With Novel Targeted Therapies for HER2-Positive Upper GI Cancers
Oct 14, 2025: I-Mab To Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 03, 2025: ALX Oncology to Present Data from Phase 2 Trial, Highlighting CD47 Expression as a Predictive Biomarker in Gastric Cancer, at 40th SITC Annual Meeting
Clinical Trial Profile Snapshots
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Table 1: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region, 2025*
Table 2: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Table 3: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Table 4: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Table 5: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Table 6: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries, 2025*
Table 7: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Table 8: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Table 9: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2025*
Table 10: Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Table 11: Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Table 12: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2025*
Table 13: Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Table 14: Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Table 15: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase, 2025*
Table 16: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Table 17: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Table 18: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Table 19: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2025
Table 20: Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Table 21: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Table 22: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Table 23: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figures
Figure 1: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region (%), 2025*
Figure 2: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Figure 3: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Figure 4: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Figure 5: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Figure 6: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Figure 7: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Figure 8: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Figure 9: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2025*
Figure 10: Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Figure 11: Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Figure 12: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2025*
Figure 13: Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Figure 14: Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Figure 15: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Figure 16: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Figure 17: Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Figure 18: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Figure 19: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2025
Figure 20: Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Figure 21: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Figure 22: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Figure 23: Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
Figure 24: GlobalData Methodology

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us